Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Epizyme Inc (NQ: EPZM )

11.79 USD -0.05 (-0.42%)
Official Closing Price Updated: 4:01 PM EST, Jan 27, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Epizyme Inc

< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
Epizyme Presents Pre-Clinical Data on EZH2 Inhibitor EPZ-6438 (E7438) in Models of Synovial Sarcoma
From Business Wire News Releases
Epizyme Announces Clinical And Pre-Clinical Data To Be Featured In Oral And Poster Presentations At American Society Of Hematology (ASH) Annual Meeting
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with ... 
Tags Benzinga EPZM News
From Benzinga
Epizyme Announces Clinical and Pre-Clinical Data to be Featured in Oral and Poster Presentations at American Society of Hematology (ASH) Annual Meeting
From Business Wire News Releases
Commit To Purchase Epizyme At $22.50, Earn 19.4% Annualized Using Options
Investors considering a purchase of Epizyme Inc. (EPZM) stock, but tentative about paying the going market price of $26.62/share, might benefit from considering selling puts among the alternative... 
Tags Stocks
From Market News Video
Epizyme Announces Clinical Data from Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) to be Presented at EORTC-NCI-AACR Symposium
From Business Wire News Releases
Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team
From PR Newswire
Epizyme, Inc. to Present at Upcoming Events in October
From Business Wire News Releases
Epizyme Appoints Peter Ho, M.D., Ph.D., as Chief Development Officer and Michael Shih, J.D., as Vice President, Business Development
From Business Wire News Releases
UPDATE: Mizuho Securities USA Initiates Coverage On Epizyme Inc On Epigenetics Pure Play
In a report published Friday, Mizuho Securities USA analyst Peter Lawson initiated coverage on Epizyme Inc (NASDAQ: EPZM) with a Buy ... 
Tags EPZM Peter Lawson Analyst Color
From Benzinga
Benzinga's Top Initiations
Analysts at Wunderlich initiated coverage on L Brands (NYSE: LB) with a Buy rating. The target price for L Brands is set to $75. L ... 
Tags Top Initiations AMSG DG
From Benzinga
Mizuho Securities Initiates Epizyme With Buy
Analysts at Mizuho Securities initiated coverage on shares of Epizyme (NASDAQ: EPZM) with a Buy rating. The target price for Epizyme ... 
Tags Mizuho Securities Initiation Benzinga
From Benzinga
Epizyme Announces Resignation Of President And CFO Jason Rhodes
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with ... 
Tags EPZM Benzinga News
From Benzinga
Epizyme Announces Resignation of President and Chief Financial Officer Jason Rhodes
From Business Wire News Releases
Epizyme to Present at Upcoming Conferences in September
From Business Wire News Releases
Softening Russian stance on Ukraine lifts markets
Conciliatory comments by Russian President Vladimir Putin lifted the markets to a higher close with the Dow climbing 61 points to 16,713. Nasdaq gained 18 points to 4453. 
Tags Market News
From MarketMinute.com Market Updates
Softening Russian stance on Ukraine lifts markets
Tags VPCO EPZM TKMR
From MarketMinute » Market Updates
BAC, JPM, MS and Volcker Rule Lead Stock Market News Today By Garrett Baldwin
Dow Jones today, August 13, 2014: U.S. stocks were in the red on Tuesday as concerns about the European markets affected investor sentiment. Geopolitical hot spots in Ukraine and in the Middle East... 
Tags Stock Market Today stock market news stock market news today
From Money Morning
Epizyme Announces Second Quarter 2014 Financial Results and Provides Corporate Update
From Business Wire News Releases
9 Biotechnology Stocks to Buy Now
 
Tags Stocks to Buy NASDAQ:ACOR NASDAQ:EPZM
From InvestorPlace
Epizyme Presents Pre-Clinical Data and Early Clinical Observations from Ongoing Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) at ASH Meeting on Lymphoma Biology
From Business Wire News Releases
Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014
From Business Wire News Releases
11 Biotechnology Stocks to Buy Now
 
Tags NASDAQ:STML NASDAQ:PCYC NASDAQ:NWBO
From InvestorPlace
Epizyme, Inc. to Report Second Quarter Financial Results and Provide Corporate Update on August 13, 2014
From Business Wire News Releases
UPDATE: H.C. Wainwright & Co. Initiates Coverage On Epizyme, Transition Therapeutics
In a note released Tuesday morning, H.C. Wainwright analyst Andrew Fein initiated a Buy on both Epizyme (NASDAQ: EPZM) and Transition ... 
Tags Price Target EPZM Analyst Color
From Benzinga
8 Biotechnology Stocks to Buy Now
 
Tags NASDAQ:ACOR Stocks to Buy NASDAQ:EPZM
From InvestorPlace
Study Updates, Market Activity, Preclinical Data, and Oral Presentations - Analyst Notes on Amicus, Conatus, Dicerna, Epizyme and Array
Editor Note: For more information about this release, please scroll to bottom 
From PR Newswire
Epizyme to Give Oral Presentation on Pre-Clinical Models and Early Clinical Observations of EZH2 Inhibitor EPZ-6438 at ASH Meeting on Lymphoma Biology August 10-13, 2014
From PR Newswire
Epizyme, Inc. to Present at Upcoming Conferences in June
From PR Newswire
Commit To Purchase Epizyme Inc. At $20, Earn 28% Annualized Using Options
Investors considering a purchase of Epizyme Inc. (EPZM) stock, but tentative about paying the going market price of $21.79/share, might benefit from considering selling puts among the alternative... 
Tags Stocks
From Market News Video
Epizyme Announces First Quarter 2014 Financial Results and Provides Corporate Update
-- Initiated pediatric MLL-r Phase 1b dose escalation study of DOT1L inhibitor EPZ-5676 in May 2014; three proof-of-concept studies ongoing with EPZ-5676 
From PR Newswire
< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account